Biotech | September 10, 2025
Evonik and Ethris partner to expand offerings for nucleic acid delivery
Accelerating RNA-based therapeutic solutions for customers through co-development of products and formulation support
Accelerating RNA-based therapeutic solutions for customers through co-development of products and formulation support
The partnership will create a first-of-its-kind, fully integrated offering for the development of mRNA drug products
Collaboration with KNAUER to streamline and improve the scale-up of LNP formulations
Wacker Biotech is a CDMO for the GMP-compliant production of active ingredients for the pharmaceutical industry
Moderna continues to expand its mRNA platform for a range of additional clinical applications and routes of administration including a modality for lung delivery
Both companies have been selected for stand-by production by German government
Adds to Merck’s growing global, multi-modality CDMO network, following newly formed CDMO business unit in Life Science
The transaction is expected to close in the first quarter of 2022
Subscribe To Our Newsletter & Stay Updated
